WOODSIDE, Calif., March 09, 2017 -- GSV Capital Corp. ("GSV Capital") (Nasdaq:GSVC) today announced that it has changed the date of its fourth quarter and fiscal year 2016 earnings conference call to 2:00 p.m. PT (5:00 p.m. ET) on Thursday, March 16, 2017. The call was previously scheduled for Monday, March 13, 2017, at 2:00 p.m. PT (5:00 p.m. ET).
The conference call access number for U.S. participants is 877-852-6543, and the conference call access number for participants outside the U.S. is 719-325-4839. The conference ID number for both access numbers is 8092483. Additionally, interested parties can listen to a live webcast of the call from the "Investor Relations" section of GSV Capital's website at http://investors.gsvcap.com/. An archived replay of the webcast will also be available for 12 months following the live presentation.
A replay of the conference call may be accessed until 5:00 p.m. PT (8:00 p.m. ET) on March 23, 2017 by dialing 888-203-1112 (U.S.) or 1 719-457-0820 (International) and using conference ID number 8092483.
The earnings press release will be available on our website prior to the beginning of the conference call.
About GSV Capital Corp.
GSV Capital Corp. (GSVC) is a publicly traded investment fund that seeks to invest in high-growth, venture-backed private companies. Led by industry veteran Michael Moe, the fund seeks to create a portfolio of high-growth emerging private companies via a repeatable and disciplined investment approach, as well as to provide investors with access to such companies through its publicly traded common stock. GSV Capital is headquartered in Woodside, CA. www.gsvcap.com
Follow GSV Capital on Twitter: @gsvcap
The GSV Capital Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=12750
Contact GSV Capital Corp. (650) 235-4769 [email protected]


Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 



